Article Text

Download PDFPDF
Prevalence and outcomes of acute pancreatitis in COVID-19: a meta-analysis
  1. Feng Yang1,
  2. Yuting Huang2,
  3. Tian Li3,
  4. Yunting Fu4,
  5. Chenyu Sun5,
  6. Yecheng Xu1,
  7. John Windsor6,
  8. Deliang Fu1
  1. 1 Department of Pancreatic Surgery, Huashan Hospital Fudan University, Shanghai, Shanghai, China
  2. 2 Department of Medicine, University of Maryland Medical Center Midtown Campus, Baltimore, Maryland, USA
  3. 3 Department of Medicine, SUNY Downstate Health and Science University, New York City, New York, USA
  4. 4 Health Sciences and Human Services Library, University of Maryland, Baltimore, Baltimore, Maryland, USA
  5. 5 Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, Chicago, Illinois, USA
  6. 6 Surgical and Translational Research Centre, The University of Auckland, Auckland, New Zealand
  1. Correspondence to Dr Feng Yang, Department of Pancreatic Surgery, Huashan Hospital Fudan University, Shanghai, Shanghai, China; yffudan98{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The study by Pandanaboyana et al 1 showed that acute pancreatitis (AP) patients with COVID-19 had a significantly higher mortality than those without COVID-19. Nevertheless, a similar trend of mortality was found by another observational cohort study.2 The true prevalence and outcomes of AP in patients with COVID-19 are not known. The aim of this study was to conduct a meta-analysis to determine the pooled prevalence and clinical outcomes of AP in patients with COVID-19.

PubMed, Embase, Scopus and Cochrane library were searched for outcome studies of adult patients with AP and COVID-19 published before 15 September 2021 (online supplemental file 1). Excluded were studies that either did not use the revised Atlanta criteria for AP diagnosis or reported patients with COVID-19 with a prior history of pancreatitis. Patients were divided into three groups: group I—AP with COVID-19, group II—AP without COVID-19 and group III—COVID-19 without AP. The primary endpoint was mortality (both in-hospital or 30-day). Secondary endpoints were pooled prevalence of AP and other clinical outcomes. The overall pooled prevalence and mortality were assessed for group I with a random-effects model and Freeman–Tukey …

View Full Text


  • Twitter @jwindsor3

  • Collaborators None.

  • Contributors Concept and design: FY, JW and DF; acquisition, analysis and interpretation of data: FY, YH, TL, YF, CS, YX, JW and DF; drafting of the manuscript: FY; critical revision of the manuscript: JW and DF. All authors finally approved the manuscript.

  • Funding The research was supported by the National Key R&D Program of China No.2017YFC1308604 (Dr Yang).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.

  • Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.